Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06290128 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

Study acronym: MOBILIZE
StatusActive, Not Recruiting
PhasePhase 3
SponsorSanofi
Started2024-07-12
View on ClinicalTrials.gov ↗
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.

Amendment history 6 changes detected by DataLookout

2026-08-11
Enrollment closed, study ongoing
2026-08-11
Enrollment reduced: 140 → 109 participants
2026-08-11
Primary completion moved earlier: 2027-05-17 → 2026-06-10
2026-08-11
Completion moved earlier: 2028-11-20 → 2027-10-31
2026-06-13
Trial sites expanded: 128 → 131 locations
2026-05-27
Trial sites expanded: 125 → 128 locations
Trial Details
NCT Number NCT06290128
Lead Sponsor Sanofi
Conditions Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Enrollment 109 participants
Start Date 2024-07-12
Primary Completion 2026-06-10 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10